DK0909183T3 - DHA-konjugerede farmaceutisk midler - Google Patents

DHA-konjugerede farmaceutisk midler

Info

Publication number
DK0909183T3
DK0909183T3 DK97926723T DK97926723T DK0909183T3 DK 0909183 T3 DK0909183 T3 DK 0909183T3 DK 97926723 T DK97926723 T DK 97926723T DK 97926723 T DK97926723 T DK 97926723T DK 0909183 T3 DK0909183 T3 DK 0909183T3
Authority
DK
Denmark
Prior art keywords
pharmaceuticals
dha conjugated
pharmaceutical agents
dha
conjugated
Prior art date
Application number
DK97926723T
Other languages
Danish (da)
English (en)
Inventor
Charles S Swindell
Matthews O Bradley
Victor E Shashoua
Nigel L Webb
Original Assignee
Luitpold Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luitpold Pharm Inc filed Critical Luitpold Pharm Inc
Application granted granted Critical
Publication of DK0909183T3 publication Critical patent/DK0909183T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)
DK97926723T 1996-05-22 1997-05-22 DHA-konjugerede farmaceutisk midler DK0909183T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/651,312 US5795909A (en) 1996-05-22 1996-05-22 DHA-pharmaceutical agent conjugates of taxanes
EP97926723A EP0909183B1 (en) 1996-05-22 1997-05-22 Dha-pharmaceutical agent conjugates

Publications (1)

Publication Number Publication Date
DK0909183T3 true DK0909183T3 (da) 2004-12-20

Family

ID=24612392

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97926723T DK0909183T3 (da) 1996-05-22 1997-05-22 DHA-konjugerede farmaceutisk midler

Country Status (10)

Country Link
US (3) US5795909A (Direct)
EP (2) EP0909183B1 (Direct)
JP (1) JP4402173B2 (Direct)
AT (1) ATE273025T1 (Direct)
AU (1) AU725759B2 (Direct)
CA (1) CA2255614C (Direct)
DE (1) DE69730217T2 (Direct)
DK (1) DK0909183T3 (Direct)
ES (1) ES2222514T3 (Direct)
WO (1) WO1997044063A2 (Direct)

Families Citing this family (257)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US20030133955A1 (en) * 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US20030068362A1 (en) * 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US20030073642A1 (en) * 1993-02-22 2003-04-17 American Bioscience, Inc. Methods and formulations for delivery of pharmacologically active agents
US5972948A (en) * 1994-07-01 1999-10-26 Solvay Pharmaceuticals Gmbh Method of inhibiting hyperglycemia and pharmaceutical composition for use therein
US6231888B1 (en) 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
EP0914116B1 (en) * 1996-05-22 2000-10-11 Protarga Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
KR100330373B1 (ko) * 1996-05-28 2002-11-07 주식회사한국신약 탁솔을 함유한 주사용 약제 조성물
US6440980B1 (en) * 1996-09-17 2002-08-27 Avanir Pharmaceuticals Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
IL132941A0 (en) * 1997-05-21 2001-03-19 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
ZA986614B (en) * 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
KR100550839B1 (ko) 1997-09-17 2006-02-10 에자이 가부시키가이샤 항균제
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20040136915A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US20090162300A1 (en) * 1997-10-01 2009-06-25 Dugger Iii Harry A Buccal, polar and non-polar spray containing alprazolam
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US20040136913A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing sumatriptan
US20030190286A1 (en) * 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US20050180923A1 (en) * 1997-10-01 2005-08-18 Dugger Harry A.Iii Buccal, polar and non-polar spray containing testosterone
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20040141923A1 (en) * 1997-10-01 2004-07-22 Dugger Harry A. Buccal, polar and non-polar spray containing alprazolam
US20050163719A1 (en) * 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
EP2042161A1 (en) * 1997-10-01 2009-04-01 Novadel Pharma Inc. Propellant-free spray composition comprising anti-emetic agent
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20050287075A1 (en) * 1997-10-01 2005-12-29 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20030077228A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
DE69922296T2 (de) * 1998-01-13 2005-10-27 Daiichi Suntory Pharma Co., Ltd. Antibakterille zusammensetzung zur topischen anwendung, enthaltend faropenem
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
UA65607C2 (uk) * 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
FI980901A7 (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaania säädellysti vapauttavia oraalisia koostumuksia
PT1736144E (pt) 1998-05-18 2016-02-10 Takeda Pharmaceutical Comprimidos de desintegração oral
US7413759B2 (en) * 1998-05-21 2008-08-19 Beech-Nut Nutrition Corporation Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
AU763309B2 (en) * 1998-07-20 2003-07-17 Smithkline Beecham Corporation Bioenhanced formulations comprising eprosartan in oral solid dosage form
ATE291418T1 (de) * 1998-07-28 2005-04-15 Takeda Pharmaceutical Leicht zerfallende feste zubereitung
WO2000009133A1 (fr) * 1998-08-10 2000-02-24 Asahi Kasei Kogyo Kabushiki Kaisha Preparations orales, a liberation prolongee, a base de chlorhydrate de fasudil
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
DE60039410D1 (de) * 1999-01-29 2008-08-21 Takeda Pharmaceutical Verdichtungshammer mit beschichtungsbehandlung
HK1040486A1 (zh) * 1999-03-09 2002-06-14 Luitpold Pharmaceuticals, Inc. 脂肪酸-抗癌共軛和其用途
US7235583B1 (en) * 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US6475984B2 (en) * 1999-04-29 2002-11-05 The Nemours Foundation Administration of leptin
US7247642B2 (en) * 1999-05-07 2007-07-24 Wockhardt Limited Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment
WO2000067802A1 (en) * 1999-05-10 2000-11-16 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
US6197337B1 (en) * 1999-05-10 2001-03-06 Kenneth Weisman Therapeutic uses of abarelix
US7175855B1 (en) * 1999-05-27 2007-02-13 Pfizer Inc. Ziprasidone suspension
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
EP1210121A2 (en) 1999-08-24 2002-06-05 Cellgate Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
WO2001017524A1 (en) * 1999-09-09 2001-03-15 Efa Sciences Llc. Methods for treating cell proliferative disorders including cancer
US6426367B1 (en) * 1999-09-09 2002-07-30 Efa Sciences Llc Methods for selectively occluding blood supplies to neoplasias
US6541508B2 (en) 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6713454B1 (en) * 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6383511B1 (en) * 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
CZ302498B6 (cs) * 1999-11-15 2011-06-15 Pharma Mar, S. A. Farmaceutický prípravek obsahující aplidin pro lécení rakovinových onemocnení
US20020045606A1 (en) * 1999-12-02 2002-04-18 Reddy Satyanarayana G. Esters of vitamin D3 and uses thereof
US6638906B1 (en) 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
US6380253B1 (en) * 2000-01-05 2002-04-30 Efa Sciences Llc Method of stabilizing and potentiating the action of anti-angiogenic substances
AU2001230994A1 (en) 2000-01-19 2001-07-31 The United States of America, represented by The Secretary, Department of Health & Human Services Use of pentosan polysulfate to treat certain conditions of the prostate
JP2003522172A (ja) * 2000-02-02 2003-07-22 フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド 抗腫瘍剤としてのｃ１０エステル置換タキサン
US6649632B2 (en) 2000-02-02 2003-11-18 Fsu Research Foundation, Inc. C10 ester substituted taxanes
AR030188A1 (es) * 2000-02-02 2003-08-13 Univ Florida State Res Found Compuestos de taxano sustituidos con esteres en el c7; composiciones farmaceuticas que los contienen y proceso para tratar un sujeto mamifero que sufre de una condicion que responde a los taxanos
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
US6660750B2 (en) 2000-02-15 2003-12-09 University Of Iowa Research Foundation Flavopiridol methods and compositions for HIV therapy
US6452024B1 (en) 2000-02-22 2002-09-17 Chaichem Pharmaceuticals International Process for extraction and purification of paclitaxel from natural sources
US20030083342A1 (en) * 2002-08-27 2003-05-01 Steele Ronald Edward Combination of organic compounds
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
AU2002222931A1 (en) 2000-07-19 2002-01-30 University Of Pittsburgh Synthesis and biological evaluation of analogs of the antimitotic marine natural product curacin a
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US6884777B1 (en) 2000-11-14 2005-04-26 The Nemours Foundation Method for treating respiratory distress syndrome
AU2002303164A1 (en) * 2001-03-23 2002-10-08 Protarga, Inc. Fatty amine drug conjugates
WO2002076404A2 (en) * 2001-03-23 2002-10-03 Protarga, Inc. Fatty alcohol drug conjugates
US20020198228A1 (en) * 2001-04-03 2002-12-26 Kaura Sita R. Composition and method for the treatment of respiratory desease
AU2002256471B2 (en) * 2001-05-03 2007-05-24 Allergan, Inc. Compositions having enhanced pharmacokinetic characteristics
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7425565B2 (en) * 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
CA2354486A1 (en) * 2001-07-31 2003-01-31 Florida State University Research Foundation, Inc. C7 ester substituted taxanes
CA2354471A1 (en) * 2001-07-31 2003-01-31 Florida State University Research Foundation, Inc. C10 ester substituted taxanes
SG125889A1 (en) * 2001-08-01 2006-10-30 Univ Florida State Res Found C7 ester subsituted taxanes
SG129990A1 (en) * 2001-08-01 2007-03-20 Univ Florida State Res Found C10 ester substituted taxanes
US6852737B2 (en) * 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
ES2379544T3 (es) * 2001-09-27 2012-04-27 Ramot At Tel Aviv University Ltd. Conjugado de perfenazina y GABA y usos del mismo
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
AU2004201240B2 (en) * 2001-09-27 2008-08-07 Bar Ilan University Conjugated Psychotropic Drugs and Uses Thereof
US6730667B2 (en) * 2001-11-26 2004-05-04 William R. Deagle Iontophoresis disc pain blocker
JP2005510537A (ja) * 2001-11-29 2005-04-21 サウンド・ファーマシューティカルズ・インコーポレイテッド 化学療法の所望されない効果を改善する方法および組成物
WO2003057207A1 (en) * 2002-01-04 2003-07-17 Sound Pharmaceuticals Incorporated Methods for treating hearing loss
CA2475092C (en) 2002-02-04 2012-05-01 Christian F. Wertz Nanoparticulate compositions having lysozyme as a surface stabilizer
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
EP1487489A4 (en) * 2002-03-04 2008-10-01 Medimmune Inc METHOD FOR PREVENTING OR TREATING ILLNESSES BY ADMINISTERING AN INTEGRIN AVB3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE
AU2003235931A1 (en) * 2002-05-13 2003-11-11 Takata Seiyaku Co., Ltd. Vintoperol-containing medicinal composition for transdermal administration
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US20040002663A1 (en) * 2002-06-26 2004-01-01 Reeves William H. Method and system for use in detecting a cancerous and precancerous pathology
AU2003261167A1 (en) * 2002-07-16 2004-02-02 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
AU2003291634A1 (en) * 2002-10-08 2004-05-04 Sepracor Inc. Fatty acid modified forms of glucocorticoids and their use as anti-inflammatory
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
WO2004052308A2 (en) * 2002-12-10 2004-06-24 Biosynexus Incorporated Topical anti-infective formulations
US7524515B2 (en) * 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
WO2004062620A2 (en) * 2003-01-13 2004-07-29 Cedars-Sinai Medical Center Paricalcitol as a chemotherapeutic agent
US6759539B1 (en) 2003-02-27 2004-07-06 Chaichem Pharmaceuticals International Process for isolation and purification of paclitaxel from natural sources
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
CN101791409A (zh) * 2003-04-22 2010-08-04 研究及应用科学协会股份有限公司 肽载体
US7429565B2 (en) 2003-04-25 2008-09-30 Gilead Sciences, Inc. Antiviral phosphonate analogs
EP1636335B1 (en) * 2003-05-28 2012-07-11 Mito Tek, LLC Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase
CA2532807A1 (en) * 2003-07-17 2005-02-03 Cotherix, Inc. Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
US20060089374A1 (en) * 2003-07-17 2006-04-27 Glenn Cornett Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
US20050187278A1 (en) * 2003-08-28 2005-08-25 Pharmacia Corporation Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
CA2537180A1 (en) * 2003-08-29 2005-03-10 Cotherix, Inc. Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
US20080045559A1 (en) * 2003-10-29 2008-02-21 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
CA2543722C (en) * 2003-10-29 2011-01-04 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
US7820839B2 (en) * 2003-10-30 2010-10-26 The Research Foundation Of State University Of New York Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
GB0326180D0 (en) * 2003-11-11 2003-12-17 Leuven K U Res & Dev Biocompatible coating of medical devices
PE20050693A1 (es) 2004-02-13 2005-09-27 Univ Florida State Res Found Taxanos sustituidos con esteres de ciclopentilo en c10
WO2005087222A1 (en) 2004-03-05 2005-09-22 Florida State University Research Foundation, Inc. C7 lactyloxy-substituted taxanes
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
CA2561513C (en) 2004-03-29 2019-02-26 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
GB0413729D0 (en) * 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
GB0413730D0 (en) * 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
HRP20070078A2 (hr) 2004-07-27 2007-05-31 Gilead Sciences Fosfonatni analozi spojeva koji inhibiraju hiv
US20060154959A1 (en) * 2005-01-13 2006-07-13 Navitas Pharma Combination therapies of cicletanine and carvedilol
US7888346B2 (en) * 2004-09-24 2011-02-15 Universtiy of Maryland, Baltimore Method of treating organophosphorous poisoning
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
US20060122127A1 (en) * 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
US20070141174A1 (en) * 2005-01-13 2007-06-21 Navitas Pharma, Inc. Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
AU2006212738B2 (en) 2005-02-09 2012-04-05 Mitotek, Llc Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase
AU2006220626A1 (en) * 2005-03-08 2006-09-14 Sound Pharmaceuticals Incorporated Methods and compositions for treating cancer
US20060216767A1 (en) * 2005-03-22 2006-09-28 Saladax Biomedical Inc. Docetaxel immunoassay
WO2006117664A1 (en) 2005-05-04 2006-11-09 Pronova Biopharma Norge As New dha derivatives and their use as medicaments
ES2400772T3 (es) * 2005-06-07 2013-04-12 Ramot At Tel Aviv University Ltd. Sales novedosas de fármacos psicotrópicos conjugados y procedimientos para la preparación de las mismas
US20070105817A1 (en) * 2005-11-09 2007-05-10 Jim Page Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
WO2007059019A2 (en) * 2005-11-14 2007-05-24 Winch Peter D Novel colored solutions of injectable drugs and their pharmaceutically acceptable salts
US8722884B2 (en) * 2005-12-01 2014-05-13 Verastem, Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
EP2343298B9 (en) 2005-12-13 2020-05-06 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
CZ300305B6 (cs) * 2005-12-20 2009-04-15 Heaton, A. S. Farmaceutická kompozice obsahující derivát taxanu se zlepšenou terapeutickou úcinností
AU2007237874A1 (en) * 2006-04-13 2007-10-25 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
EP2015632B1 (en) * 2006-04-19 2015-12-02 Mist Pharmaceuticals, LLC Stable hydroalcoholic oral spray formulations and methods
PT2020996E (pt) * 2006-05-16 2012-02-20 Gilead Sciences Inc Método e composições para tratar neoplasias malignas hematológicas
FR2902659A1 (fr) 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
EP2051735B1 (en) 2006-07-17 2012-08-29 Ramot, at Tel Aviv University Ltd. Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use treating pain and other cns disorders
WO2008014456A2 (en) * 2006-07-28 2008-01-31 Collegium Pharmaceutical, Inc. Combination therapy for otitis with antiseptic and ph adjustment
WO2008021242A2 (en) * 2006-08-10 2008-02-21 The Research Foundation Of State University Of New York Fluorotaxoid-fatty acid conjugates and pharmaceutical compositions thereof
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
CA2667211A1 (en) 2006-11-01 2008-05-08 Pronova Biopharma Norge As Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar)
CN101611029B (zh) * 2006-12-21 2014-09-10 辉瑞产品公司 2-((4-(1-甲基-4-(吡啶-4-基)-1h-吡唑-3-基)苯氧基)甲基)喹啉的琥珀酸盐
WO2008079295A1 (en) * 2006-12-22 2008-07-03 Novadel Pharma Inc. Stable anti-nausea oral spray formulations and methods
CA2674367A1 (en) * 2007-01-03 2008-07-17 Glenn V. Cornett Cicletanine and pkc inhibitors in the treatment of pulmonary and cardiac disorders
TWI384986B (zh) * 2007-01-17 2013-02-11 Lg Life Sciences Ltd 抗病毒劑之順丁烯二酸單鹽以及含有該單鹽之醫藥組成物
EP2167493A1 (en) * 2007-03-09 2010-03-31 Novartis AG Salts of 3- (1h-ind0l-3-yl) -4- [2- (4-methyl-piperazin-i-yl) -quinazolin-4-yl]-pyrrole-2,5-di one
US9220837B2 (en) * 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
US20080280947A1 (en) * 2007-05-10 2008-11-13 Blondino Frank E Anti-insomnia compositions and methods
US20090099062A1 (en) * 2007-05-31 2009-04-16 Ethan Lee Pyrvinium For The Treatment of Cancer
RS53245B2 (sr) 2007-06-13 2022-10-31 Incyte Holdings Corp Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
US8067632B2 (en) * 2007-07-26 2011-11-29 The Board Of Trustees Of The Leland Stanford Junior University Process to produce prostratin and structural or functional analogs thereof
UA99836C2 (en) * 2007-09-26 2012-10-10 Маунт Синай Скул Оф Медсин Azacytidine analogue and using thereof
US7985325B2 (en) * 2007-10-30 2011-07-26 Novellus Systems, Inc. Closed contact electroplating cup assembly
CA2709219A1 (en) * 2007-12-12 2009-06-18 Ultimorphix Technologies B.V. Solid forms of tenofovir disoproxil
PE20091156A1 (es) * 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
US8207369B2 (en) 2008-02-11 2012-06-26 Ramot At Tel-Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
JP2011517455A (ja) 2008-03-31 2011-06-09 フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド Ｃ（１０）エチルエステルおよびｃ（１０）シクロプロピルエステル置換タキサン
AU2009234127B2 (en) * 2008-04-10 2015-04-30 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
BRPI0912170A2 (pt) * 2008-05-13 2015-10-13 Astrazeneca Ab composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
US8835506B2 (en) 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
PT2307435E (pt) * 2008-07-08 2012-09-19 Gilead Sciences Inc Sais de compostos inibidores de vih
US9085527B2 (en) 2008-07-08 2015-07-21 Catabasis Pharmaceuticals, Inc. Fatty acid acylated salicylates and their uses
PT2315740T (pt) 2008-07-08 2018-01-30 Catabasis Pharmaceuticals Inc Salicilatos acetilados de ácido gordo e suas utilizações
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
CA3090738C (en) * 2008-12-01 2023-06-13 Oyster Point Pharma, Inc. Synthesis and salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
EP2375900B1 (en) * 2008-12-11 2016-03-02 Biovista, Inc. Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles
MA32961B1 (fr) * 2008-12-18 2012-01-02 Novartis Ag Sel hemifumarate d'acide 1-[4-[1(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl]-2-ethyl -benzyl]-azetidine-3-carboxylique
US9034389B2 (en) 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US8993625B2 (en) * 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
AU2010233097B2 (en) * 2009-04-10 2016-04-07 Abraxis Bioscience, Llc Nanoparticle formulations and uses thereof
WO2010135468A1 (en) * 2009-05-19 2010-11-25 Vivia Biotech S.L. Methods for providing personalized medicine tests ex vivo for hematological neoplasms
HRP20192203T1 (hr) 2009-05-22 2020-03-06 Incyte Holdings Corporation 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- ili heptan-nitril kao jak inhibitori
TW201113285A (en) * 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
AU2010329440A1 (en) 2009-12-09 2012-08-09 Bar-Ilan University Methods of improving cognitive functions
BR112012016879A2 (pt) 2010-01-08 2015-09-01 Catabasis Pharmaceuticals Inc Derivados de fumarato de acido graxo e seus usos
SI3354652T1 (sl) 2010-03-10 2020-08-31 Incyte Holdings Corporation Derivati piperidin-4-il azetidina kot inhibitorji JAK1
MY161078A (en) 2010-05-21 2017-04-14 Incyte Holdings Corp Topical formulation for a jak inhibitor
US8916610B2 (en) 2010-09-22 2014-12-23 Ramot At Tel-Aviv University Ltd. Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
JP5917545B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
WO2012154554A1 (en) * 2011-05-06 2012-11-15 Catabasis Pharmaceuticals, Inc. Fatty acid triterpene derivatives and their uses
PE20140832A1 (es) 2011-06-20 2014-07-14 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
CN102952138B (zh) * 2011-08-17 2016-07-06 上海特化医药科技有限公司 一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
RS53995B1 (sr) 2011-09-19 2015-10-30 Orexo Ab Nove farmaceutske kompozicije, otporne na zloupotrebu, za tretman zavisnosti od opioida
WO2013168021A1 (en) * 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
TWI702057B (zh) 2012-11-15 2020-08-21 美商英塞特控股公司 盧梭利替尼之緩釋性劑型
ES2900492T3 (es) 2013-03-06 2022-03-17 Incyte Holdings Corp Procesos y productos intermedios para elaborar un inhibidor de JAK
RS60469B1 (sr) 2013-08-07 2020-07-31 Incyte Corp Dozni oblici sa produženim oslobađanjem za jak1 inhibitor
WO2015116782A1 (en) 2014-01-29 2015-08-06 Board Of Regents, The University Of Texas System Nucleobase analogue derivatives and their applications
US9505709B2 (en) 2014-05-05 2016-11-29 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
BR112016029476A2 (pt) 2014-06-18 2017-08-22 Thetis Pharmaceuticals Llc complexos de aminoácido mineral de agentes ativos
CN104225615B (zh) * 2014-09-24 2017-02-01 东南大学 一种紫杉醇类磷脂化合物、其药物组合物及应用
WO2016198971A1 (en) * 2015-06-08 2016-12-15 Mohan M Alapati Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
US20190125702A1 (en) * 2016-03-15 2019-05-02 Vitality Biopharma, Inc. Methods and Compositions for the Treatment of Demyelinating Disorders
DK3454907T3 (da) 2016-06-03 2020-10-19 Thetis Pharmaceuticals Llc Sammensætninger og fremgangsmåder relateret til salte af specialiserede pro-løsningsmediatorer af inflammation
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
SI3490560T1 (sl) 2016-07-29 2025-04-30 Janssen Pharmaceutica, N.V. Niraparib za uporabo pri metodi zdravljenja raka prostate
WO2019027920A1 (en) 2017-08-01 2019-02-07 Gilead Sciences, Inc. CRYSTALLINE FORMS OF ETHYL ((S) - (((((2R, 5R) -5- (6-AMINO-9H-PURIN-9-YL) -4-FLUORO-2,5-DIHYDROFURAN-2-YL) OXY ) METHYL) (PHENOXY) PHOSPHORYL) -L-ALANINATE (GS-9131) FOR THE TREATMENT OF VIRAL INFECTIONS
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
PT3746429T (pt) 2018-01-30 2022-06-20 Incyte Corp Processos para a preparação de (1-(3-fluoro-2-(trifluorometil)isonicotinoíl)piperidin-4-ona)
EP4424328A3 (en) 2018-03-30 2024-12-04 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
AU2019255233A1 (en) 2018-04-17 2020-11-26 Cardurion Pharmaceuticals, Llc Meglumine salts of thienopyrimidines
US11897928B2 (en) 2018-07-18 2024-02-13 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
WO2020018888A1 (en) 2018-07-20 2020-01-23 The Board Of Regents Of The University Of Oklahoma Antimicrobial peptides and methods of use
US11040038B2 (en) 2018-07-26 2021-06-22 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
EP3941897A4 (en) * 2019-03-22 2023-04-05 Integrated Nanotherapeutics Inc. LIPID CONJUGATE MADE FROM A FRAMEWORK PART
MX2022006176A (es) 2019-11-22 2022-08-17 Incyte Corp Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2.
MX2022009050A (es) 2020-01-22 2022-10-27 Seelos Therapeutics Inc Reduccion de los efectos secundarios de los antagonistas de nmda.
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN119606959A (zh) * 2024-12-26 2025-03-14 典晶医药(无锡)有限公司 Tazofelone与紫杉类药物的组合物在治疗实体瘤中的应用

Family Cites Families (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US449A (en) * 1837-11-11 Improvement in the mode of preparing paint for the protection of buildings against fire
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3621048A (en) 1968-03-14 1971-11-16 Colgate Palmolive Co Quaternary ammonium compounds
US4218234A (en) 1972-12-07 1980-08-19 Novex Rt. Soil conditioners
SU477159A1 (ru) 1973-07-27 1975-07-15 Всесоюзный научно-исследовательский институт фитопатологии Способ получени амидофосфорилоксиэтиламидов карбоновых кислот
AR208187A1 (es) 1973-12-05 1976-12-09 Pfizer Metodo para la preparacion derivados de n-carbamoil-2-feniletensulfonamida
JPS5186479A (en) 1975-01-22 1976-07-29 Asahi Chemical Ind 55 furuororashirujudotainoseizohoho
DE2602175B2 (de) 1975-01-22 1978-05-03 Asahi Kasei Kogyo K.K., Osaka (Japan) 1 -Alkanoyl-5-fluor-uracilderivate und ihre Verwendung
US4097597A (en) 1977-02-23 1978-06-27 Abbott Laboratories Dibenzo b,e! 1,4!diazepines
US4351831A (en) 1977-11-02 1982-09-28 Massachusetts Institute Of Technology Process and composition for treating disorders by administering isoxsurpine and choline
US4287184A (en) 1977-11-23 1981-09-01 The Massachusetts General Hospital Process for healing wounds
US4407744A (en) 1977-11-23 1983-10-04 Young David M Process for obtaining nerve growth factor
US4185095A (en) 1977-11-23 1980-01-22 The Massachusetts General Hospital Nerve growth factor
CH622660GA3 (Direct) 1978-08-18 1981-04-30
JPS5553208A (en) 1978-10-13 1980-04-18 Mitsubishi Chem Ind Ltd Insecticide
IT7927748A0 (it) * 1979-11-30 1979-11-30 Simes Derivati dell'acido 6,6'-diapopsi psicarotenedioico e relativi procedimenti di preparazione.
US4408052A (en) 1980-02-27 1983-10-04 Takeda Chemical Industries, Ltd. Phospholipid carbamates
US4346085A (en) * 1980-02-29 1982-08-24 Massachusetts Institute Of Technology Process and composition for treating disorders by administering amphetamine and choline
US4636494A (en) * 1981-01-30 1987-01-13 Massachusetts Institute Of Technology Process and composition for treating disorders by administering amphetamine and choline
JPS58177953A (ja) * 1982-04-13 1983-10-18 Eisai Co Ltd ポリプレニルカルボン酸アミドおよびその製造方法
JPS5925327A (ja) 1982-07-31 1984-02-09 Hidematsu Hirai 抗腫瘍性複合体の製造方法
US4558049A (en) 1982-11-24 1985-12-10 Farmitalia Carlo Erba S.P.A. Antipsycotic benzoxazines
US5169762A (en) 1983-03-03 1992-12-08 Genentech, Inc. Human nerve growth factor by recombinant technology
JPS59204175A (ja) 1983-04-28 1984-11-19 Terumo Corp ５―フルオロウラシル誘導体を有効成分とする血小板凝集抑制剤
EP0133795B1 (en) 1983-08-01 1989-01-18 THE McLEAN HOSPITAL CORPORATION Gaba esters and gaba analogue esters
US4704393A (en) * 1983-10-20 1987-11-03 Terumo Kabushiki Kaisha 1-substituted 5-fluorouracil useful for inhibiting the aggregation of platelets
US4550109A (en) * 1984-05-31 1985-10-29 The Board Of Regents, The University Of Texas System Lipoidal biopterin compounds
US4684646A (en) * 1984-06-26 1987-08-04 Merck & Co., Inc. 2-acylaminomethyl-1,4-benzodiazepine derivatives as CCK-antagonists
US4868161A (en) 1984-06-29 1989-09-19 City Of Hope Method for promoting nerve regeneration
IL72684A (en) 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4554272A (en) * 1985-01-25 1985-11-19 Merck & Co., Inc. Substituted quinazolino-1,4-benzodiazepin-6,9-diones and their preparation
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US6448392B1 (en) 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
JPS61204136U (Direct) 1985-06-05 1986-12-23
US4729989A (en) 1985-06-28 1988-03-08 Merck & Co., Inc. Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts
US4692441A (en) 1985-08-16 1987-09-08 Merck & Co., Inc. Chorine esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities
US5246726A (en) 1986-03-21 1993-09-21 Efamol Ltd. Iron-containing composition and method for treatment of cancer
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2601676B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4968672A (en) 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US5459256A (en) 1987-04-17 1995-10-17 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Lipophilic, aminohydrolase-activated prodrugs
SE8703625D0 (sv) 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
JPH03501253A (ja) 1987-09-22 1991-03-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア エイズ（ａｉｄｓ）治療を目的とするリポソームによるヌクレオシド類似物質
US4943579A (en) 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
ZA886890B (en) 1987-10-09 1989-05-30 Hoffmann La Roche Novel dideoxycytidine derivatives
US5420276A (en) 1987-11-03 1995-05-30 Abbott Laboratories Analogs of oxetanyl purines and pyrimidines
JPH01153629A (ja) 1987-12-11 1989-06-15 Nippon Oil & Fats Co Ltd 制癌剤
JPH01203331A (ja) 1988-02-05 1989-08-16 Rikagaku Kenkyusho 制癌剤
US4933324A (en) * 1988-02-26 1990-06-12 Shashoua Victor E Fatty acid-neuroactive drug conjugate as a prodrug
US4939174A (en) * 1988-02-26 1990-07-03 Shashoua Victor E Appetite suppression with dopamine-fatty acid conjugates
US5284876A (en) 1988-02-26 1994-02-08 Neuromedica, Inc. Method of treating tardive dyskinesia using dopaminergic agents of prodrugs of therapeutic agents
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US6107499A (en) 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
JPH01287022A (ja) 1988-05-12 1989-11-17 Nippon Oil & Fats Co Ltd 抗癌剤耐性克服剤
GB8813766D0 (en) 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
US6252060B1 (en) 1988-07-07 2001-06-26 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
JP2612619B2 (ja) 1988-12-14 1997-05-21 財団法人相模中央化学研究所 含リン化合物よりなる経皮吸収促進剤
CH676909A5 (Direct) 1988-12-23 1991-03-28 Nestle Sa
HU207287B (en) 1989-01-17 1993-03-29 Biosignal Kutato Fejlesztoe Kf Polyene fatty acid derivatives of tyrozine-quinaze inhibiting activity and pharmaceutical composition containing them as active component
US5216142A (en) 1989-04-17 1993-06-01 Efamol Holdings Plc Anti-virals
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
GB8918294D0 (en) 1989-08-10 1989-09-20 Efamol Holdings Pharmaceutical compositions
JPH03236315A (ja) 1989-12-05 1991-10-22 Nippon Oil & Fats Co Ltd 抗精神病薬
GB9001121D0 (en) 1990-01-18 1990-03-21 Efamol Holdings Efa compositions and therapy
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5545719A (en) 1990-05-01 1996-08-13 Neuromedica, Inc. Nerve growth peptides
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
US5169764A (en) 1990-08-08 1992-12-08 Regeneron Pharmaceuticals, Inc. Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras
JP3139777B2 (ja) 1990-08-27 2001-03-05 フマキラー株式会社 組換えダニアレルゲン
US5278324A (en) 1990-08-28 1994-01-11 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5059699A (en) 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
WO1992016554A1 (en) 1991-03-14 1992-10-01 The University Of Melbourne Protein allergens of the species cynodon dactylon
GB9108056D0 (en) 1991-04-16 1991-06-05 Hale Geoffrey Synthetic antigen
WO1992020362A1 (en) * 1991-05-14 1992-11-26 Shashoua Victor E Nerve growth peptides and uses therefor
DE4122722A1 (de) 1991-07-06 1993-01-07 Schering Ag Verfahren zur herstellung von indol-derivaten
US5227369A (en) 1991-07-11 1993-07-13 The Regents Of The University Of California Compositions and methods for inhibiting leukocyte adhesion to cns myelin
JPH07502274A (ja) 1991-12-10 1995-03-09 ラシユ−プレスビタリアン−セントルークス・メデイカル・センター 多薬剤耐性を低下させる方法および組成物
US5369191A (en) * 1992-01-23 1994-11-29 Kureha Kagaku Kogyo K.K. Aromatic thioether ketone/thioether sulfone copolymer and production process thereof
IT1254515B (it) * 1992-03-06 1995-09-25 Indena Spa Tassani di interesse oncologico, loro metodo di preparazione ed uso
IT1254517B (it) * 1992-03-06 1995-09-25 Indena Spa 14-beta idrossi-10-deacetil-baccatina iii, suoi derivati, loro prepazione ed impiego terapeutico
US5214062A (en) 1992-04-08 1993-05-25 Clintec Nutrition Co. Method and composition for treating immune disorders, inflammation and chronic infections
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
JPH0616548A (ja) 1992-06-30 1994-01-25 Sagami Chem Res Center 組織異常増殖抑制剤
US5308832A (en) 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
DE4224737A1 (de) 1992-07-27 1994-02-03 Herbert Prof Dr Schott Neue Cytosinnucleosidanaloga, Verfahren zu ihrer Herstellung und ihre Verwendung
US5352596A (en) 1992-09-11 1994-10-04 The United States Of America As Represented By The Secretary Of Agriculture Pseudorabies virus deletion mutants involving the EPO and LLT genes
US5453521A (en) * 1992-10-05 1995-09-26 Rhone-Poulenc Rorer S.A. Process for obtaining 10-deacetylbaccatin III
FR2696461B1 (fr) * 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
US5356928A (en) * 1992-11-06 1994-10-18 Hauser Chemical Research, Inc. Cytotoxic agents
FR2697841B1 (fr) * 1992-11-12 1995-01-13 Rhone Poulenc Rorer Sa Nouveaux dérivés du taxane, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2698269B1 (fr) 1992-11-24 1995-01-06 Inst Nat Sante Rech Med Nouveaux médicaments à base d'acides gras insaturés, utilisables notamment comme antiagrégants plaquettaires et/ou comme transporteurs privilégiés vers le cerveau.
GB9224809D0 (en) 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
CA2150470A1 (en) * 1992-11-30 1994-06-09 S.P.I. Synthetic Peptides Incorporated Polyunsaturated fatty acyl-peptide composition
FR2698871B1 (fr) * 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5496714A (en) 1992-12-09 1996-03-05 New England Biolabs, Inc. Modification of protein by use of a controllable interveining protein sequence
GB9300125D0 (en) 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
GB9301629D0 (en) 1993-01-27 1993-03-17 Scotia Holdings Plc Formulations containing unsaturated fatty acids
GB9304746D0 (en) 1993-03-09 1993-04-28 Scotia Holdings Plc Treatment of viral infections
IL105244A (en) 1993-03-31 2003-07-31 Dpharm Ltd Prodrugs with enhanced penetration into cells
US6413949B1 (en) 1995-06-07 2002-07-02 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
GB9307043D0 (en) 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
US5643909A (en) * 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
US5336684A (en) * 1993-04-26 1994-08-09 Hauser Chemical Research, Inc. Oxidation products of cephalomannine
FR2707293A1 (fr) * 1993-07-08 1995-01-13 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
FR2712289B1 (fr) * 1993-11-08 1996-01-05 Rhone Poulenc Rorer Sa Nouveaux dérivés de taxicine, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2712288B1 (fr) * 1993-11-08 1996-01-05 Rhone Poulenc Rorer Sa Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5480799A (en) 1993-12-10 1996-01-02 The University Of North Carolina At Chapel Hill Sperm antigen corresponding to a sperm zona binding protein autoantigenic epitope
IT1264987B1 (it) 1993-12-14 1996-10-17 Prospa Bv Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
GB9403857D0 (en) 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
US5925669A (en) * 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
US5468754A (en) * 1994-04-19 1995-11-21 Bionumerik Pharmaceuticals, Inc. 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
US5604198A (en) 1994-05-12 1997-02-18 Poduslo; Joseph F. Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
FR2721023B1 (fr) * 1994-06-09 1996-07-12 Rhone Poulenc Rorer Sa Nouveaux Taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
JPH0815133A (ja) 1994-06-29 1996-01-19 Hitachi Ltd 分析素子
FR2721928A1 (fr) * 1994-07-04 1996-01-05 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
US5597719A (en) 1994-07-14 1997-01-28 Onyx Pharmaceuticals, Inc. Interaction of RAF-1 and 14-3-3 proteins
JPH0827010A (ja) 1994-07-19 1996-01-30 Nichinichi Seiyaku Kk 制癌免疫療法剤
AU3275595A (en) * 1994-08-05 1996-03-04 Molecular/Structural Biotechnologies, Inc. Site-specific biomolecular complexes
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
NL9401743A (nl) 1994-10-20 1996-06-03 Prospa Bv Zouten van aminoalcoholen en farmaceutische formuleringen die deze bevatten.
JPH08163991A (ja) 1994-12-15 1996-06-25 Mitsui Petrochem Ind Ltd タキサン型ジテルペンの製造方法
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
CA2210500A1 (en) 1995-01-16 1996-07-25 Commonwealth Scientific And Industrial Research Organisation Therapeutic compound - fatty acid conjugates
JPH11511732A (ja) 1995-03-06 1999-10-12 インターニューロン ファーマシューティカルズ，インコーポレーテッド シチコリンを用いる梗塞容積の低減
US5977061A (en) 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
MY118354A (en) 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
US5532374A (en) 1995-06-06 1996-07-02 Hitachi Chemical Company, Ltd. Method of preparation of bis-quinolines
JPH0925231A (ja) 1995-07-13 1997-01-28 Sagami Chem Res Center 癌転移抑制剤
JPH0930963A (ja) 1995-07-21 1997-02-04 Nisshin Oil Mills Ltd:The 医療用油脂含有組成物
JP3372259B2 (ja) 1995-09-21 2003-01-27 ウィスコンシン・アルムニ・リサーチ・ファウンデーション カルシトリオール誘導体およびそれらの用途
US5952317A (en) 1995-09-21 1999-09-14 Wisconsin Alumni Research Foundation Calcitriol derivatives and their uses
US5646180A (en) 1995-12-05 1997-07-08 Vertex Pharmaceuticals Incorporated Treatment of the CNS effects of HIV
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
EP0914116B1 (en) * 1996-05-22 2000-10-11 Protarga Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
AU770519B2 (en) 1996-05-22 2004-02-26 Luitpold Pharmaceuticals, Inc. DHA-pharmaceutical agent conjugates
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
GB9618420D0 (en) 1996-09-04 1996-10-16 Scotia Holdings Plc Fatty acid treatment
US5976784A (en) 1996-09-20 1999-11-02 Wisconsin Alumni Research Foundation Calcitriol derivatives and their uses
KR20000053226A (ko) 1996-11-12 2000-08-25 요나스 프릭 뉴클레오사이드
JPH10168047A (ja) 1996-12-04 1998-06-23 Kao Corp アミド誘導体及びこれを含有する外用剤組成物
GB2321455A (en) 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
US5977174A (en) 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6153653A (en) 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US5955459A (en) 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
GB9804361D0 (en) 1998-03-02 1998-04-22 Scotia Holdings Plc Cancer treatment
US6136988A (en) 1998-04-10 2000-10-24 Hauser, Inc. 7-hexanoyltaxol and methods for preparing the same
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
HK1040486A1 (zh) 1999-03-09 2002-06-14 Luitpold Pharmaceuticals, Inc. 脂肪酸-抗癌共軛和其用途
US6184164B1 (en) * 1999-04-28 2001-02-06 The University Of Houston Bimodal silicon nitride-bas ceramic composites
WO2000067802A1 (en) 1999-05-10 2000-11-16 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
US6459645B2 (en) 1999-09-30 2002-10-01 Intel Corporation VPX bank architecture
US6710086B1 (en) 2000-02-25 2004-03-23 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
CN1520297A (zh) 2001-04-26 2004-08-11 ���ߵ���Ƶϵͳ��˾ 包含复合药物(codrugs)的缓释药物传递系统

Also Published As

Publication number Publication date
US20020010208A1 (en) 2002-01-24
US6602902B2 (en) 2003-08-05
US20040180949A1 (en) 2004-09-16
EP1466628A1 (en) 2004-10-13
CA2255614C (en) 2009-12-15
DE69730217T2 (de) 2005-07-28
CA2255614A1 (en) 1997-11-27
WO1997044063A2 (en) 1997-11-27
JP2000514405A (ja) 2000-10-31
ATE273025T1 (de) 2004-08-15
DE69730217D1 (de) 2004-09-16
WO1997044063A3 (en) 1998-02-26
AU725759B2 (en) 2000-10-19
ES2222514T3 (es) 2005-02-01
US7199151B2 (en) 2007-04-03
US5795909A (en) 1998-08-18
EP0909183B1 (en) 2004-08-11
JP4402173B2 (ja) 2010-01-20
AU3142597A (en) 1997-12-09
EP0909183A2 (en) 1999-04-21

Similar Documents

Publication Publication Date Title
DK0909183T3 (da) DHA-konjugerede farmaceutisk midler
CA2310850A1 (en) A covalent conjugate of clozapine with a fatty acid and its use for treating schizophrenia
BR9506820A (pt) Derivados de 4-amino de ácido micofenólico
ATE297762T1 (de) Peg-lhrh analog konjugate
IL132398A0 (en) Piperazine derivatives and their use as anti-inflammatory agents
EP0659211A4 (en) METHOD AND THERAPEUTIC COMPOSITIONS FOR TREATING CYSTIC FIBROSE.
FI955320L (fi) Bioaktiivisia ja/tai kohdennettuja dendriimikonjugaatteja
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
ATE208382T1 (de) Konjugate von cis-docosahexaensäure und paclitaxel
MY130110A (en) 6-substituted mycophenolic acid and derivatives
DE69703294D1 (de) Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten
ATE406382T1 (de) Tropoelastinderivate
PT1224205E (pt) Derivados 5-beta-sapogenina e pseudo-sapogenina e sua utilizacao no tratamento de demencia
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
DE69935140D1 (de) Verwendung von anabolika, anti-katabolischen mitteln, antioxidanzien und analgetika zum schutz, zur behandlung und reparation von bindegeweben in menschen und tieren
NO20052925D0 (no) Vannloselige anioniske bakterieklorofyllderivater og deres anvendelse
HK1040486A1 (zh) 脂肪酸-抗癌共軛和其用途
PT932400E (pt) Derivados de anticonvulsionantes uteis no tratamento da dor neuropatica
GB9509888D0 (en) Terpenoidic derivatives useful as antitumour agents
DE59802925D1 (de) Verfahren zum herstellen von extrakt enthaltenden pharmazeutischen formulierungen
ATE210126T1 (de) 4-amino-6-substituierte mycophenolsäurederivate mit immunsuppressiver wirkung
BR9506838A (pt) Derivados de ácido micofenólico substituídos na posição 5
BR9710992A (pt) Derivados anticovulsivos úteis no tratamento de psorìase
DK0810223T3 (da) Adamantylsubstituerede oxindoler som farmaceutiske midler
UA36385A (uk) Спосіб лікування генералізованого пародонтиту